ARS Pharmaceuticals, Inc. (SPRY)
5.89
-0.14
(-2.32%)
USD |
NASDAQ |
Aug 28, 16:00
5.89
0.00 (0.00%)
After-Hours: 20:00
ARS Pharmaceuticals Enterprise Value : 538.52M for Aug. 28, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 28, 2026 | 538.52M |
| August 27, 2026 | 552.44M |
| August 26, 2026 | 552.44M |
| August 25, 2026 | 521.62M |
| August 24, 2026 | 484.82M |
| August 21, 2026 | 500.24M |
| August 20, 2026 | 500.24M |
| August 19, 2026 | 587.24M |
| August 18, 2026 | 579.29M |
| August 17, 2026 | 573.32M |
| August 14, 2026 | 514.66M |
| August 13, 2026 | 559.40M |
| August 12, 2026 | 554.43M |
| August 11, 2026 | 544.49M |
| August 10, 2026 | 540.51M |
| August 07, 2026 | 565.37M |
| August 06, 2026 | 504.71M |
| August 05, 2026 | 485.82M |
| August 04, 2026 | 481.84M |
| August 03, 2026 | 495.76M |
| July 31, 2026 | 462.95M |
| July 30, 2026 | 512.67M |
| July 29, 2026 | 532.55M |
| July 28, 2026 | 516.64M |
| July 27, 2026 | 525.59M |
| Date | Value |
|---|---|
| July 24, 2026 | 543.49M |
| July 23, 2026 | 549.46M |
| July 22, 2026 | 555.42M |
| July 21, 2026 | 585.26M |
| July 20, 2026 | 593.21M |
| July 17, 2026 | 648.90M |
| July 16, 2026 | 694.64M |
| July 15, 2026 | 703.59M |
| July 14, 2026 | 709.55M |
| July 13, 2026 | 722.48M |
| July 10, 2026 | 742.37M |
| July 09, 2026 | 736.40M |
| July 08, 2026 | 758.28M |
| July 07, 2026 | 767.23M |
| July 06, 2026 | 781.15M |
| July 02, 2026 | 804.02M |
| July 01, 2026 | 742.37M |
| June 30, 2026 | 749.33M |
| June 29, 2026 | 745.56M |
| June 26, 2026 | 743.58M |
| June 25, 2026 | 691.94M |
| June 24, 2026 | 942.18M |
| June 23, 2026 | 916.36M |
| June 22, 2026 | 886.57M |
| June 18, 2026 | 853.80M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Passage Bio, Inc. | -9.610M |
| Vertex Pharmaceuticals, Inc. | 131.35B |
| Capricor Therapeutics, Inc. | 410.38M |
| Kyntra Bio, Inc. | -36.84M |
| Zentalis Pharmaceuticals, Inc. | 135.42M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -62.34M |
| Revenue (Quarterly) | 33.66M |
| Total Expenses (Quarterly) | 96.00M |
| EPS Diluted (Quarterly) | -0.6277 |
| Gross Profit Margin (Quarterly) | 61.83% |
| Profit Margin (Quarterly) | -185.2% |
| Earnings Yield | -36.89% |
| Normalized Earnings Yield | -36.91 |